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A benign fibrous histiocytoma with primary site of origin in the parietal bone has not yet been reported in the literature.
We report here a case concerning a 12-year-old girl with a 14-month history of an enlarging parietal bone mass. The
tumor was excised after removal of the cortical bone and resection of the tumor surrounding the cortical bone erosion
using pre-plasticity titanium repair. Both postoperative histopathological examination and immunohistochemical analysis
were consistent with a benign fibrous histiocytoma. No clinical or computed tomography (CT) radiological signs of tumor
recurrence and/or metastasis were observed at 12 months. Although a primary benign fibrous histiocytoma of the parietal
bone is a rare tumor, it should be considered as a potential diagnosis for any cranial tumor. Surgical intervention is the
most effective treatment technique for a benign fibrous histiocytoma.
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A benign fibrous histiocytoma (BFH) is a rare tumor of
the skeleton and accounts for approximately 1% of all
surgically treated benign bone tumors. BFHs of the cra-
nial bones are exceedingly rare and have been described
in the skull base, frontal bone, and facial cranium. We
report here the first known case of a BFH in the parietal
bone, including its diagnosis, surgical excision, and a re-
view of the literature.Case presentation
History
A 12-year-old girl presented with a 14-month history of
an enlarging parietal bone mass, without pain and cra-
nial nerve deficits. The mass measured 4.0 × 3.0 cm. A
computed tomography (CT) scan demonstrated a lesion
within the parietal bone mass. The tumor exhibited low
density, an irregular shape, and was associated with ero-
sion of internal and external bony plates resulting from
osteolytic destruction (Figure 1A, B).* Correspondence: bieli@aliyun.com
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Surgery was performed on the patient under general
anesthesia, and the external plate of the parietal bone
was found to be perforated. The tumor was excised,
followed by removal of the cortical bone and resection
of the tumor surrounding the cortical bone erosion. Fur-
ther resection was performed to remove damaged bone
from the remaining normal structure of cortical bone,
with completion of repair using pre-plasticity titanium
mesh. A portion of the tumor, located just above the sa-
gittal sinus, was carefully removed to avoid damage to
the sinus during surgery.Follow-up
The patient recovered well from the operation. No
clinical or CT radiological signs of tumor recurrence
and/or metastasis were detected at 6 months and 12
months post-surgery (Figure 1D). Postoperative histo-
pathological examination revealed the proliferation of
spindle-shaped fibroblasts arranged in a storiform pat-
tern (Figure 2A). There were some histiocytic foamy
cells scattered within the background of the fibroblasts
described above. No malignant characteristics, such as
nuclear atypia, pleomorphism, or atypical mitosis were
observed. Immunohistochemical analysis was per-
formed on the formalin-fixed, paraffin-embedded sec-
tions using the streptavidin-biotin-peroxidase complexhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Preoperative CT images of bone-window revealed a low
density mass, irregular shape, internal and external bony plates
eroded. (A) On axial CT scan. (B) On sagittal CT scan. (C) A 3D
reconstructed image by CT showed external bony plates to be
jacked up. (D) Postoperative CT scan of the axial showing no
tumor recurrence 12 months after operation.
Figure 2 Microphotographs of specimen histology showing the
proliferation of spindle-shaped fibroblasts arranged in a storiform
pattern. There were some histiocytic foamy cells scattered under
the background of the above (hematoxylin and eosin, original
magnification ×200) (A). Microphotographs of specimen histology
showing the tumor cells positive for Vimentin (B), partially positive
for CD68 (C), negative for S-100 (D), GFAP (E), CD34 (F), EMA (G)
and SMA (H). They confirmed the diagnosis of benign fibrous
histiocytoma (immunohistochemical staining, original
magnification ×200).
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for vimentin, partially positive for CD68, and negative
for S100 protein, glial fibrillary acidic protein (GFAP),
CD34, epithelial membrane antigen (EMA), and
smooth muscle actin (SMA) (Figure 2B,C,D,E,F,G,H).
These findings strongly indicate a histiocytic origin for
this tumor. Fewer than 1% of cells stained positive for
Ki-67 (data not shown).
Discussion
BFH usually occurs in the dermis, superficial subcutane-
ous tissue, and deep soft tissues [1]. BFH located in the
skeleton is rare, with only about 100 total reported cases.
BFHs of bones frequently arise in the flat bones, includ-
ing the tibia, pelvic bone, and femur [2]. BFH in the
cerebral cranium has not been reported, while only four
cases have been recorded in the skull base or frontal
bone (Table 1). These lesions are more common in
males, with a male-to-female ratio of 2.5:1 and tend to
occur in young patients with mean age of 37 years [3].
In one report, a BFH was noted in an 11 month-old-girl
during drainage of a middle ear infection [4]. The pa-
tient in the case report described here was 12 years old.
Patients with BFH of the cranial bone usually present
with symptoms which vary with the specific cranial bone
location impacted by the tumor. In one report, occlusion
of the right transverse sinus in patients with a right oc-
cipital protrusion presented with tenderness and hori-
zontal diplopia [2]. Wen et al. found that such patientsmay have symptoms of tumor oppression of the eye [5].
In other cases, if the tumor invaded the pterygopalatine
fossa, this has been observed to cause trigeminal nerve
hypesthesia, serous otitis media, and decreased man-
dibular excursion (on the right side in that case) [6]. In
the parietal bone BFH tumor described in this report,
the tumor exhibited slow growth and was asymptomatic,
creating no obvious clinical effects but was found during
a shower.
Imaging plays an important role in the diagnosis and
identification of BFH. It is our suggestion that CT should
be used as a first-line imaging tool in any patient pre-
senting with clinical symptoms of skull tumors. A CT
scan usually detects low density or isodensity lesions in
bone. BFH shows extra compartmental extensions with
somewhat irregular edges and bone defects, as exhibited
Table 1 Summary of reported cases of cerebral cranium
Number Age (years) Sex Location Interval (months)a Treatment Reference
1 45 Male Skull base 2 Surgery Fritz et al., 2006 [6]
2 0.9 Female Skull base 0b Biopsy Shane tubbs et al., 2007 [4]
3 33 Male Skull base 2 Surgery Iedguchi et al., 2009[8]
4 22 Male Frontal bone 15 Surgery Wen et al., 2010 [5]
aNumber of years between initial be noted of tumor and surgery of the tumor; btumor was noted during drainage of a middle ear infection.
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scans of typical areas of ground-glass density may con-
firm the diagnosis of craniofacial fibrous dysplasia [8].
Such lesions are eccentric and multi- or uniloculated
and are well demarcated with a sclerotic rim. A diag-
nosis of nonossifying fibroma can be made with CT
scan with an accuracy of 100% [9]. CT images of BFH
show a slow-growing tumor such as an expanded
intradiploic space, expansive remodeling, and foci of
pressure erosion, in some cases, demonstrating osteo-
lytic changes [10]. In our case, the CT scan showed
thinning of the cortex, in addition to bone defects.
Diagnosis using MRI and PET scans is still in the ex-
ploratory stage for detection of BFH. In one pilot
study, the tumor in question exhibited homogeneous
enhancement by CT with contrast, Gd-enhanced MR
imaging, and moderate uptake of FDG in the FDG-
PET scan. These imaging methodologies are likely to
be very useful for future diagnosis [2].
The lesions in BFH are described as lytic; most ex-
hibit sharply defined margins and a sclerotic rim. The
histopathological characteristics of BFH in bone in-
clude the proliferation of fibrohistiocytic cells with a
storiform or swirl pattern, lipid-filled cells, foam cells,
and giant cells that fill the gaps in the fiber network
system. Little nuclear atypia, pleomorphism, or necro-
sis are observed [11]. In our case, fibrohistiocytic cells
with a storiform pattern and no nuclear atypia, pleo-
morphism, or atypical mitosis were observed with a
Ki-67 labeling index of <1%.
Complete excision of the tumor is the best treat-
ment option. If lesions are found in the significant
area of the skull base, a biopsy could be performed to
confirm the diagnosis. However, in the case presented
here, the tumor was located in the parietal bone;
pathological diagnosis did not affect the tumor resec-
tion outcome. Radiotherapy has only been attempted
in one case but was only of modest benefit and there-
fore would play only a very limited role in the treat-
ment of BFH [6].
Follow-up is very important to monitor for tumor re-
currence or metastasis. Bielamowica et al. reported an
11% recurrence rate after local resection of BFH of the
head and neck [3]. Therefore, a CT scan is recom-
mended for follow-up assessment.Conclusions
In conclusion, primary BFH of the parietal bone is rarely
observed but should be considered as a possible diagno-
sis of any cranial tumor. Surgical intervention should
aim to achieve gross total resection in order to gain the
highest chance for a definitive cure. Moreover, radiother-
apy and chemotherapy should be individualized to meet
the needs of each BFH patient.
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